BR112016011048A8 - processo para preparar um composto, processos para fabricar compostos, compostos e composições farmacêuticas - Google Patents

processo para preparar um composto, processos para fabricar compostos, compostos e composições farmacêuticas Download PDF

Info

Publication number
BR112016011048A8
BR112016011048A8 BR112016011048A BR112016011048A BR112016011048A8 BR 112016011048 A8 BR112016011048 A8 BR 112016011048A8 BR 112016011048 A BR112016011048 A BR 112016011048A BR 112016011048 A BR112016011048 A BR 112016011048A BR 112016011048 A8 BR112016011048 A8 BR 112016011048A8
Authority
BR
Brazil
Prior art keywords
compounds
preparing
compound
processes
pharmaceutical compositions
Prior art date
Application number
BR112016011048A
Other languages
English (en)
Other versions
BR112016011048A2 (pt
BR112016011048B1 (pt
Inventor
Gosselin Francis
Iding Hans
Scalone Michelangelo
Reents Reinhard
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of BR112016011048A2 publication Critical patent/BR112016011048A2/pt
Publication of BR112016011048A8 publication Critical patent/BR112016011048A8/pt
Publication of BR112016011048B1 publication Critical patent/BR112016011048B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165Heterorings having nitrogen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

a presente invenção refere-se a um processo para preparar um composto de fórmula (i) em que r1 é como definido aqui, que é útil como um intermediário na preparação de compostos farmacêuticos ativos.
BR112016011048-0A 2013-11-15 2014-11-13 Processo para preparar um composto e composto BR112016011048B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13193030.7 2013-11-15
EP13193030 2013-11-15
PCT/US2014/065567 WO2015073739A1 (en) 2013-11-15 2014-11-13 Processes for the preparation of pyrimidinylcyclopentane compounds

Publications (3)

Publication Number Publication Date
BR112016011048A2 BR112016011048A2 (pt) 2017-08-08
BR112016011048A8 true BR112016011048A8 (pt) 2020-04-22
BR112016011048B1 BR112016011048B1 (pt) 2024-04-16

Family

ID=

Also Published As

Publication number Publication date
EP3656764B1 (en) 2023-07-05
HRP20231100T1 (hr) 2023-12-22
RU2019130505A (ru) 2020-02-18
US10858324B2 (en) 2020-12-08
RU2016123365A (ru) 2017-12-18
IL281072A (en) 2021-04-29
JP6374503B2 (ja) 2018-08-15
IL281072B (en) 2022-05-01
IL271331B (en) 2021-03-25
IL245636B (en) 2019-12-31
CN110590606B (zh) 2023-02-17
CN105899492A (zh) 2016-08-24
KR20220139440A (ko) 2022-10-14
MX2016006299A (es) 2017-02-22
JP2018052966A (ja) 2018-04-05
MX2020009462A (es) 2021-08-31
MX2019006959A (es) 2019-08-01
AU2022275477A1 (en) 2023-01-05
US10435378B2 (en) 2019-10-08
US20180086722A1 (en) 2018-03-29
KR20160075816A (ko) 2016-06-29
AU2021202196A1 (en) 2021-05-06
CN105899492B (zh) 2021-08-24
KR102493603B1 (ko) 2023-01-31
HUE063095T2 (hu) 2023-12-28
EP3656764A1 (en) 2020-05-27
AR098427A1 (es) 2016-05-26
CA3207199A1 (en) 2015-05-21
PL3068770T3 (pl) 2020-04-30
MY174153A (en) 2020-03-11
EP3068770A4 (en) 2017-04-19
AU2014348570A1 (en) 2016-06-09
CA2930870A1 (en) 2015-05-21
JP2021100953A (ja) 2021-07-08
ES2765511T3 (es) 2020-06-09
JP2016539939A (ja) 2016-12-22
WO2015073739A1 (en) 2015-05-21
US9862689B2 (en) 2018-01-09
CN110590606A (zh) 2019-12-20
SI3068770T1 (sl) 2020-02-28
KR102698200B1 (ko) 2024-08-26
JP2019218384A (ja) 2019-12-26
ES2957314T3 (es) 2024-01-17
EP3068770B1 (en) 2019-10-23
MY191759A (en) 2022-07-14
HK1223102A1 (zh) 2017-07-21
US20160297773A1 (en) 2016-10-13
JP6857219B2 (ja) 2021-04-14
RU2702355C1 (ru) 2019-10-08
BR112016011048A2 (pt) 2017-08-08
CN112898210A (zh) 2021-06-04
US20200062717A1 (en) 2020-02-27
HRP20192340T1 (hr) 2020-04-03
JP6634428B2 (ja) 2020-01-22
IL271331A (en) 2020-01-30
NZ720805A (en) 2022-01-28
EP4282973A2 (en) 2023-11-29
CA2930870C (en) 2023-09-19
SG10201901578UA (en) 2019-03-28
MX367620B (es) 2019-08-28
IL245636A0 (en) 2016-06-30
EP3656764C0 (en) 2023-07-05
AU2019202461B2 (en) 2021-01-14
AU2024205845A1 (en) 2024-09-05
JP7377828B2 (ja) 2023-11-10
AU2019202461A1 (en) 2019-05-02
EP4282973A3 (en) 2024-03-27
AU2014348570B2 (en) 2019-02-28
PL3656764T3 (pl) 2024-01-22
ZA201603434B (en) 2020-08-26
ZA202002611B (en) 2023-10-25
EP3068770A1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112014030365A2 (pt) síntese de composto antiviral
BR112015027432B8 (pt) 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
BR112015033042A8 (pt) composto de azina, processos para a preparação de composto de azina, composição agroquímica, processo para a preparação de composições agroquímicas, método para controlar vegetação e uso do composto de azina
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
BR112016007356A2 (pt) compostos herbicidas
CL2016000382A1 (es) Procesos para preparar compuestos antivirales
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
BR112018006519A2 (pt) compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente
GT201500247A (es) Imidazopiridazinas sustituidas
BR112015014583B1 (pt) compostos, processo para a preparação de compostos, compostos intermediários, composição, usos de um composto de fórmula i e método para combater fungos nocivos
BR112018010140A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
BR112018010316A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
BR112014009760A8 (pt) análogos de ácido siálico
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds
BR112016018594B8 (pt) Método para produção do derivado de 2-aciliminopiridina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023011034-0 PROTOCOLO 870230047971 EM 05/06/2023 16:05.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2014, OBSERVADAS AS CONDICOES LEGAIS